Antibiotics By Diagnosis (Peds): Difference between revisions

No edit summary
No edit summary
Line 180: Line 180:
<br>  
<br>  


<br>
<br>  
 
==  ==
 
==  ==
 
 


== Febrile Syndromes/Bloodstreatm Infections<br>  ==
== Febrile Syndromes/Bloodstreatm Infections<br>  ==
Line 186: Line 192:
{| cellspacing="0" cellpadding="2" border="1" align="left"
{| cellspacing="0" cellpadding="2" border="1" align="left"
|-
|-
| Fever of Uncertain Source (FUS)
| Fever of Uncertain Source (FUS)  
| Infant &amp; Child (2-36 months)
| Infant &amp; Child (2-36 months)  
|  
|  
Workup: If well-appearing, and parents, MD and PMD confortable with follow up, consider no testing. If in season, consider testing for RSV, enterovirus or influenza.
Workup: If well-appearing, and parents, MD and PMD confortable with follow up, consider no testing. If in season, consider testing for RSV, enterovirus or influenza.  


Urine: UTI most common serious bacterial infection in males (uncircumcised or &lt;6 months) or females &lt;2 years. Other risk factors include Tmax &gt;39 or Caucasian race.
Urine: UTI most common serious bacterial infection in males (uncircumcised or &lt;6 months) or females &lt;2 years. Other risk factors include Tmax &gt;39 or Caucasian race.  


Blood: CBC and blood culture only if ill-appearing or at 'high-risk' for serious bacterial infection.
Blood: CBC and blood culture only if ill-appearing or at 'high-risk' for serious bacterial infection.  


|-
|-
| rowspan="2" | Septic shock syndromes
| rowspan="2" | Septic shock syndromes  
| Bacteremic: ''S. pneumo, N. meningitidis, Hib'' (if not immunized)
| Bacteremic: ''S. pneumo, N. meningitidis, Hib'' (if not immunized)  
| rowspan="1" | Replete intravascular volume, maximize delivery of oxygen to tissues. Blood cultures. Ceftriaxone 50 mg/kg/day IV/IM Q24 or Cefotaxime 150 mg/kg/day IV div Q8 until afebrile x24 hours.
| rowspan="1" | Replete intravascular volume, maximize delivery of oxygen to tissues. Blood cultures. Ceftriaxone 50 mg/kg/day IV/IM Q24 or Cefotaxime 150 mg/kg/day IV div Q8 until afebrile x24 hours.
|-
|-
| Toxic shock syndromes: ''Staphylococcal ''(less often associated with deep tissue disease), ''Streptococcal''
| Toxic shock syndromes: ''Staphylococcal ''(less often associated with deep tissue disease), ''Streptococcal''  
| rowspan="1" |  
| rowspan="1" |  
'''Empiric therapy should include Clindamycin and ß-lactam antibiotic until etiology is isolated.'''
'''Empiric therapy should include Clindamycin and ß-lactam antibiotic until etiology is isolated.'''  


'''Staphylococcal: '''Most often associated with toxin-producing organism at a mucosal site, may involved disease at a deeper site. Associated with tampon use, wound infection or burns. 5-15% case fatality rate. Rx: Nafcillin AND clindamycin as initial therapy. Can also use Cefazolin or Vancomycin in place of Nafcillin if MRSA suspected. IVIG 1 g/kg may bind toxins, but should be reserved for life-threatening infections.
'''Staphylococcal: '''Most often associated with toxin-producing organism at a mucosal site, may involved disease at a deeper site. Associated with tampon use, wound infection or burns. 5-15% case fatality rate. Rx: Nafcillin AND clindamycin as initial therapy. Can also use Cefazolin or Vancomycin in place of Nafcillin if MRSA suspected. IVIG 1 g/kg may bind toxins, but should be reserved for life-threatening infections.  


'''Streptococcal: '''f ''GAS'', hypotension, renal impairment, coagulopathy, ARDS and soft tissue necrosis. Associated with erisypelas, necrotizing fascitis, secondary infection of varicella. Rx: Once streptococcus is identified, change therapy to Pencillin or other ß-lactam antibiotic PLUS Clindamycin.
'''Streptococcal: '''f ''GAS'', hypotension, renal impairment, coagulopathy, ARDS and soft tissue necrosis. Associated with erisypelas, necrotizing fascitis, secondary infection of varicella. Rx: Once streptococcus is identified, change therapy to Pencillin or other ß-lactam antibiotic PLUS Clindamycin.  


|-
|-
| rowspan="2" | Central line infection
| rowspan="2" | Central line infection  
| ''Coagulase-negative Staph (CONS), S. aureus, GN-bacilli, Candida spp.''
| ''Coagulase-negative Staph (CONS), S. aureus, GN-bacilli, Candida spp.''  
| rowspan="1" |  
| rowspan="1" |  
''Coagular-negative Staph (CONS)'': can try to salvage catheter with 10-14 days of therapy (Vancomycin), 80% cure rate for exit site infections, 25% if deeper.
''Coagular-negative Staph (CONS)'': can try to salvage catheter with 10-14 days of therapy (Vancomycin), 80% cure rate for exit site infections, 25% if deeper.  


If ''S. aureus'', ''GN-bacilli'' or ''Candida'': always remove the catheter if possible. ''S. aureus ''has a 10% exit site cure rate and 0% deeper infection cure rate if catheter left in.
If ''S. aureus'', ''GN-bacilli'' or ''Candida'': always remove the catheter if possible. ''S. aureus ''has a 10% exit site cure rate and 0% deeper infection cure rate if catheter left in.  


If septic thrombophlebitis, endocarditis, osteomyelitis or repeated positive cultures, ALWAYS remove catheter.
If septic thrombophlebitis, endocarditis, osteomyelitis or repeated positive cultures, ALWAYS remove catheter.  


|-
|-
| TPN/Intralipids: as above and ''Malassezia furfur''
| TPN/Intralipids: as above and ''Malassezia furfur''  
| rowspan="1" | Remove catheter and discontinue antimicrobials if possible. If ''Candida albicans'', treat with Fluconazole 6-12 mg/kg/day IV Q24 (if &gt;14 days old) x 28 days OR conventional Amphotericin B 1 mg/kg/day IV div Q24. If ''Staph epi'', treat with Vancomycin and discontinue intralipids. If ''M. furfur'', treat with conventional Amphotericin B.
| rowspan="1" | Remove catheter and discontinue antimicrobials if possible. If ''Candida albicans'', treat with Fluconazole 6-12 mg/kg/day IV Q24 (if &gt;14 days old) x 28 days OR conventional Amphotericin B 1 mg/kg/day IV div Q24. If ''Staph epi'', treat with Vancomycin and discontinue intralipids. If ''M. furfur'', treat with conventional Amphotericin B.
|-
|-
Line 239: Line 245:
|}
|}


<br>


 
<br>
 


g[[Image:Bugs and Drugs Page 02.png|962x669px|Bugs and Drugs Page 02.png]]  
g[[Image:Bugs and Drugs Page 02.png|962x669px|Bugs and Drugs Page 02.png]]  

Revision as of 15:13, 9 July 2011

Bugs & Drugs


Neonatal Infections

NOTE: All doses listed below are for patients >2 kg and at least 7 days of age

Any infant who has tachycardia out of proportion to fever or HR >180 in any age group has a serious bacterial infection (SBI) until proven otherwise. Other serious risk factors include lethargy, hyperventiliation, cyanosis, poor perfusion and hypotonia. Have a high suspicion and treat accordingly. Always treat for meningitis until you are sure it is not. Note that bacterial etiology and antimicrobial therapies are similar for all neonatal illnesses.

Fever of Uncertain Source (FUS)

Neonatal (0-30 days): GBS, E. coli, Klebsiella, Enterobacter, Listeria or S. aureus (rare)

Send blood, urine and CSF cultures. Listeria, while infrequent at CCHMC, may sporadically occur in clustered cases.

  1. Ampicillin 200 mg/kg/day (if >2 kg) IV div Q6 AND Cefotaxime 200 mg/kg/day IV div Q6.
  2. Ampicillin 200 mg/kg/day (if >2 kg) IV div Q6 AND Gentamicin 3.5 mg/kg/day IV Q24.
  3. Consider risk factors for neonatal HSV disease. Test and treat accordingly.
Neonatal (30-60 days): See above.

Workup: Blood and urine specimen. If low-risk (non-ill appearing), normal blood and urine analyses, parents and PMD okay, consider no LP, no antibiotics, and discharge home with f/u in 12-24 hours. Otherwise, LP + Abx.

  1. Cefotaxime 200 mg/kg/day IV div Q6 or Ceftriaxone1 100 mg/kg/day IV div Q12. If evidence of UTI or severly ill infant, add Ampicillin.
Meningitis
Preterm to 60 days: GBS (49%), E. coli (18%), Listeria (7%), misc GN's, GP's
  1. Ampicillin 400 mg/kg/day (if >2 kg) IV div Q6 (if >7 days) AND Cefotaxime 200 mg/kg/day IV div Q6 (if >7 days).
  2. Ampicillin 400 mg/kg/day (if >2 kg) IV div Q6 (if >7 days) AND Gentamicin 4 mg/kg/day IV Q24.

If GBS meningitis, treat 21 days. If GN meningitis, treat 21 days (and >14 days after CSF sterilizes). Tailor therapy when specific etiology known

Neonatal HSV
HSV type 1 or 2

Risk greatest under 3 weeks of age. Greatest risk factors is primary maternal HSV at delivery.

Conjunctival disease may be manifestation of SEM disease.

  1. Acyclovir 20 mg/kg/dose Q8 IV x 21 days for CNS or disseminated disease. No role for oral acyclovir for known or suspected HSV disease. Add Trifluridine ophthalmic solution Q2 hours for ocular involvement. Always refer to Ophthalmologist immediately.
Pneumonia
GBS, Listeria, coliforms, S. aureus, Pseudomonas. If AF pneumonitis: Chlamydia, syphilis. Viruses: CMV, HSV, rubella.
  1. Ampicillin 200 mg/kg/day (if >2 kg) IV div Q6 (if >7 days) AND Cefotaxime 200 mg/kg/day IV div Q6 (if >7 days).
  2. Ampicillin 200 mg/kg/day (if >2 kg) IV div Q6 (if >7 days) AND Gentamicin 3.5 mg/kg/day IV Q24.
  3. If suspect Chlamydia (afebrile, IgM >1:8, exposure, staccato cough), add Erythromycin ethyl succinate 40 mg/kg/day PO div Q6 x 14 days.
  4. Tailor therapy when specific pathogen identified.
Osteomyelitis
Newborn period: S. aureus, GN-bacilli, GBS, Gonococcus

Often afebrile, best predictor is localizing signs. 2/3 have positive blood cultures. Surgical drainage imperative. Seek etiologic diagnosis and tailor therapy.

Empirix treatment: Nafcillin 200 mg/kg/day IV div Q6 AND Cefotaxime 150 mg/kg/day IV div Q8 for >21 days.

Send joint fluid for cultures and treat based on etiology identified.

UTI
GBS, GN-rods, Listeria, S. aureus

Pursue imagain as outlined in CCHMC guidelines: www.cincinnatichildrens.org/guidelines.

<2 weeks: Ampicillin 100 mg/kg/day IV div Q6 (or Q12 if <7 days) AND Gentamicin 3 mg/kg/day IV Q24 OR Cefotaxime 150 mg/kg/day IV div Q8

2 weeks - 2 months: Ampicillin 100 mg/kg/day IV div Q6 AND Cefotaxime 150 mg/kg/day div Q8

Neonatal conjunctivits

Neonatal: Determine cause and treatment by number of post-delivery days to onset.

Prophylaxis is Erythromycin 0.5% ointment x1 or Tetracycline 1% or Silver Nitrate 1% x1 topical, applied at birth.

Onset 2-4 days: N. gonorrheae

Hyperpurulent. Topical treatment insufficient. Evaluate for Chlamydia. Treat mother and partners.

  1. Ceftriaxone 25-50 mg/kg IV/IM x1 (max 125 mg); cannot be used in neonates requiring calcium-containing fluids OR Cefotaxime 100 mg/kg IV/IM x1. May treat >1 day for severe cases. Always irrigate eyes with saline.
Onset 3-10 days: C. trachomatis
  1. Erythromycin 50 mg/kg/day x10-14 days. Treat mother and partners. 20% have concomitant pneumonia.
  2. Azithromycin 20 mg/kg/day x3 days shown to be effective.
Onset 6-14 days: HSV
Consider if serous discharge (not mucopurulent), bulbar injection and corneal dendrites on fluorescein exam. Consult ophtho immediately!









































Febrile Syndromes/Bloodstreatm Infections

Fever of Uncertain Source (FUS) Infant & Child (2-36 months)

Workup: If well-appearing, and parents, MD and PMD confortable with follow up, consider no testing. If in season, consider testing for RSV, enterovirus or influenza.

Urine: UTI most common serious bacterial infection in males (uncircumcised or <6 months) or females <2 years. Other risk factors include Tmax >39 or Caucasian race.

Blood: CBC and blood culture only if ill-appearing or at 'high-risk' for serious bacterial infection.

Septic shock syndromes Bacteremic: S. pneumo, N. meningitidis, Hib (if not immunized) Replete intravascular volume, maximize delivery of oxygen to tissues. Blood cultures. Ceftriaxone 50 mg/kg/day IV/IM Q24 or Cefotaxime 150 mg/kg/day IV div Q8 until afebrile x24 hours.
Toxic shock syndromes: Staphylococcal (less often associated with deep tissue disease), Streptococcal

Empiric therapy should include Clindamycin and ß-lactam antibiotic until etiology is isolated.

Staphylococcal: Most often associated with toxin-producing organism at a mucosal site, may involved disease at a deeper site. Associated with tampon use, wound infection or burns. 5-15% case fatality rate. Rx: Nafcillin AND clindamycin as initial therapy. Can also use Cefazolin or Vancomycin in place of Nafcillin if MRSA suspected. IVIG 1 g/kg may bind toxins, but should be reserved for life-threatening infections.

Streptococcal: f GAS, hypotension, renal impairment, coagulopathy, ARDS and soft tissue necrosis. Associated with erisypelas, necrotizing fascitis, secondary infection of varicella. Rx: Once streptococcus is identified, change therapy to Pencillin or other ß-lactam antibiotic PLUS Clindamycin.

Central line infection Coagulase-negative Staph (CONS), S. aureus, GN-bacilli, Candida spp.

Coagular-negative Staph (CONS): can try to salvage catheter with 10-14 days of therapy (Vancomycin), 80% cure rate for exit site infections, 25% if deeper.

If S. aureus, GN-bacilli or Candida: always remove the catheter if possible. S. aureus has a 10% exit site cure rate and 0% deeper infection cure rate if catheter left in.

If septic thrombophlebitis, endocarditis, osteomyelitis or repeated positive cultures, ALWAYS remove catheter.

TPN/Intralipids: as above and Malassezia furfur Remove catheter and discontinue antimicrobials if possible. If Candida albicans, treat with Fluconazole 6-12 mg/kg/day IV Q24 (if >14 days old) x 28 days OR conventional Amphotericin B 1 mg/kg/day IV div Q24. If Staph epi, treat with Vancomycin and discontinue intralipids. If M. furfur, treat with conventional Amphotericin B.



gBugs and Drugs Page 02.png

Bugs and Drugs Page 03.png

Bugs and Drugs Page 04.png

Bugs and Drugs Page 05.png


Bugs and Drugs Page 07.png

Bugs and Drugs Page 08.png

Bugs and Drugs Page 09.png

Bugs and Drugs Page 10 real.png

Bugs and Drugs Page 10.png

Source

Cincinnati Children's Hospital "The Pocket" 2010-2011